RSPO4 and neoplasm: Consistently, luciferase reporter assay showed that RSPO4 FUm1/2 mutant lost the inhibitory effect on Wnt/β-catenin signaling and target genes in both LGR4+/LGR5- and LGR4-/LGR5+ tumor cell lines (Fig. 4D).